FDA to Review Perrigo’s Birth Control Pill for OTC Use in November

Published on September 12, 2022

Imagine the FDA as a group of experts gathering around the table to examine Perrigo’s birth control pill and decide if it can be sold over-the-counter. It’s like a panel of judges deliberating on whether a talented singer should win a singing competition or not! The FDA meeting is scheduled for November 18th, and Perrigo is eagerly waiting for their decision. Access to contraception has been a hot topic lately, as more people advocate for easier and more affordable options. If the FDA gives Perrigo the green light, it could mean that people will have more convenient access to birth control without needing a prescription. This could be a game-changer for many individuals who struggle with obtaining contraceptives. It will also be interesting to see what factors the FDA considers when evaluating the application. Will they prioritize safety, effectiveness, or both? Further research into Perrigo’s birth control pill for OTC use could shed light on new developments in contraception and provide insights into expanding access to reproductive healthcare options.

Perrigo Co Plc said on Monday that the U.S. Food and Drug Administration has scheduled a meeting of external experts on Nov. 18 to review the application of its daily birth control pill for over-the-counter (OTC) use. Contraception access has taken the spotlight since the…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>